HomeALKS • NASDAQ
add
Alkermes Plc
Nakaraang pagsara
$28.42
Sakop ng araw
$27.90 - $28.46
Sakop ng taon
$22.90 - $32.88
Market cap
4.54B USD
Average na Volume
1.51M
P/E ratio
14.32
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 378.14M | -0.73% |
Gastos sa pagpapatakbo | 210.29M | -8.67% |
Net na kita | 92.38M | 93.44% |
Net profit margin | 24.43 | 94.82% |
Kita sa bawat share | 0.73 | 14.06% |
EBITDA | 111.73M | 3.59% |
Aktuwal na % ng binabayarang buwis | 15.82% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 908.86M | 2.22% |
Kabuuang asset | 2.16B | -5.44% |
Kabuuang sagutin | 863.18M | -6.55% |
Kabuuang equity | 1.29B | — |
Natitirang share | 161.80M | — |
Presyo para makapag-book | 3.56 | — |
Return on assets | 12.01% | — |
Return on capital | 15.82% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 92.38M | 93.44% |
Cash mula sa mga operasyon | 81.59M | -18.17% |
Cash mula sa pag-invest | -109.33M | 8.40% |
Cash mula sa financing | -111.11M | -7,190.87% |
Net change in cash | -138.86M | -667.84% |
Malayang cash flow | 31.74M | -63.37% |
Tungkol
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
Itinatag
1987
Website
Mga Empleyado
2,100
